A recent retrospective analysis of real-world data published in Clinical Lymphoma, Myeloma, and Leukemia, evaluated treatment outcomes in patients with follicular lymphoma (FL) grades 1-3A receiving frontline bendamustine plus rituximab (BR)...
A recent retrospective analysis of real-world data published in Clinical Lymphoma, Myeloma, and Leukemia, evaluated treatment outcomes in patients with follicular lymphoma (FL) grades 1-3A receiving frontline bendamustine plus rituximab (BR)...
Mosunetuzumab adds a highly effective, fixed-duration treatment option for patients with relapsed or refractory (R/R) follicular lymphoma (FL), with minimal financial impact to payers.
Mosunetuzumab adds a highly effective, fixed-duration treatment option for patients with relapsed or refractory (R/R) follicular lymphoma (FL), with minimal financial impact to payers.
A matching-adjusted indirect comparison found that lisocabtagene maraleucel demonstrated improved efficacy and a favorable safety profile compared with mosunetuzumab in patients with relapsed or refractory follicular lymphoma treated in the...
A matching-adjusted indirect comparison found that lisocabtagene maraleucel demonstrated improved efficacy and a favorable safety profile compared with mosunetuzumab in patients with relapsed or refractory follicular lymphoma treated in the...
Recent advancements in bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment landscape for patients with relapsed or refractory follicular lymphoma (RR-FL), offering new hope for...
Recent advancements in bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment landscape for patients with relapsed or refractory follicular lymphoma (RR-FL), offering new hope for...
A 3-year follow-up of a phase 1/2 study confirms that mosunetuzumab, a CD20×CD3 bispecific antibody, provides durable remissions, high response rates, and a favorable safety profile in relapsed or refractory follicular lymphoma, reinforcing...
A 3-year follow-up of a phase 1/2 study confirms that mosunetuzumab, a CD20×CD3 bispecific antibody, provides durable remissions, high response rates, and a favorable safety profile in relapsed or refractory follicular lymphoma, reinforcing...
Follicular regulatory T cells (Tfr) are a potential target in treating follicular lymphoma (FL), the most common indolent B-cell lymphoma, according to study results published in Frontiers in Immunology.
Follicular regulatory T cells (Tfr) are a potential target in treating follicular lymphoma (FL), the most common indolent B-cell lymphoma, according to study results published in Frontiers in Immunology.
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
A push for a hybrid payment model for primary care is gaining momentum, with advocates urging the CMS to implement changes to increase funding and improve outcomes for patients.
A push for a hybrid payment model for primary care is gaining momentum, with advocates urging the CMS to implement changes to increase funding and improve outcomes for patients.
Research that will be presented at AMCP 2024 suggests that mepolizumab treatment reduces health care costs and resource utilization in patients with chronic rhinosinusitis with nasal polyps.
Research that will be presented at AMCP 2024 suggests that mepolizumab treatment reduces health care costs and resource utilization in patients with chronic rhinosinusitis with nasal polyps.
Keratoconus, an eye disorder that leads to gradual curvature of the cornea, may be associated with Demodex infestation, suggests a small study published in the Oman Journal of Ophthalmology.
Keratoconus, an eye disorder that leads to gradual curvature of the cornea, may be associated with Demodex infestation, suggests a small study published in the Oman Journal of Ophthalmology.
In this interview, Alison Lum, PharmD, vice president of Pharmacy Services at Blue Shield, discussed the panel she moderated at Asembia 2024 and delved into drug payment options' challenges, including the limitations of copay cards and the...
In this interview, Alison Lum, PharmD, vice president of Pharmacy Services at Blue Shield, discussed the panel she moderated at Asembia 2024 and delved into drug payment options' challenges, including the limitations of copay cards and the...
NICA 2024 session speaker Ashley Joseph of LeanTaas shares insights on how AI technologies are revolutionizing infusion therapy operations, improving care coordination, and ultimately enhancing the patient experience in these critical care...
NICA 2024 session speaker Ashley Joseph of LeanTaas shares insights on how AI technologies are revolutionizing infusion therapy operations, improving care coordination, and ultimately enhancing the patient experience in these critical care...